Advancing the therapeutic potential of the IL‐1 family in inflammatory diseases – Meeting report
Open Access
- 7 January 2019
- journal article
- editorial
- Published by Wiley in European Journal of Immunology
- Vol. 49 (1) , 8-10
Abstract
No abstract availableFunding Information
- Health Research Board (KEDS‐2017‐002)
This publication has 19 references indexed in Scilit:
- Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1Nature, 2018
- Protein tyrosine phosphatase PTPN22 regulates IL‐1β dependent Th17 responses by modulating dectin‐1 signaling in miceEuropean Journal of Immunology, 2017
- Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trialThe Lancet, 2017
- IL-36γ signaling controls the induced regulatory T cell–Th9 cell balance via NFκB activation and STAT transcription factorsMucosal Immunology, 2017
- Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family CytokinesCell Reports, 2016
- Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunityJournal of Allergy and Clinical Immunology, 2016
- Epithelial-derived IL-18 regulates Th17 cell differentiation and Foxp3+ Treg cell function in the intestineMucosal Immunology, 2015
- Succinate is an inflammatory signal that induces IL-1β through HIF-1αNature, 2013
- A clinical perspective of IL‐1β as the gatekeeper of inflammationEuropean Journal of Immunology, 2011
- IL-1 family nomenclatureNature Immunology, 2010